CEO: Here’s why Corteva moved its HQ to Indy from Delaware
Speaking at Monday’s Economic Club of Indiana, Corteva CEO Chuck Magro said last year’s decision was anything but hasty or haphazard.
John Russell
Articles
High-stakes dispute between Lilly, competitor over migraine drugs winding down
The two companies have been battling for years over patents for migraine headache drugs—Emgality for Lilly and Anjovy for Teva. Both drugs are once-monthly injections and were approved 13 days apart in September 2018.
AES Indiana reaches agreement to raise electricity rates 7.3%
The utility’s initial proposal provoked widespread objections, including from more than 40 customers who attended two field hearings.
16 Tech gears up in reach for national stage
The live-work-play campus has been picked to join a new national network designed to connect researchers, entrepreneurs and investors to accelerate the development of health care products and services and speed up health care innovations.
Lilly Endowment awards $11M to 19 local groups serving immigrants
The Indianapolis-based philanthropy giant says the grants are intended to help immigrants acclimate to life in central Indiana and make progress toward self-sufficiency.
Baxter sells Bloomington plant with 1,000 workers to private investors
The Bloomington plant, with about 1,000 employees, is the fifth-largest employer in Monroe County, according to the Greater Bloomington Chamber of Commerce, and is poised for more growth.
There are riches, risks when private-equity firms acquire medical practices
Some warn that the spiraling number of deals could lead to large physician groups having an unfairly high market share, which could lead to price increases and cost-cutting.
In face of low investor interest, Lilly again extends $1.4B offer for Point Biopharma
The extension comes amid pushback from several investors, including Point’s largest institutional stock holder.
Lilly to build $2.5B factory in Germany for injectable drugs
The announcement represents the company’s latest move to meet the soaring demand for its medicines for diabetes and weight loss.
Carmel sanitizing device maker 3Oe Scientific files for bankruptcy
The business makes a hand-sanitizing device called Iggy that kills pathogens with ozone-infused water instead of soap or other chemicals.
Lilly’s proposed $1.4B acquisition of Point Biopharma gets investor pushback
Point has a pipeline of clinical and preclinical-stage compounds in development for the treatment of cancer using radiopharmaceutical isotopes that hold the promise of delivering targeted treatments to cancer patients.
Rising hospital CEO pay raises flags
Consumer advocates and other across the country and in central Indiana are saying big executive-compensation packages are ripe for review.
Republic Services to build plastics recycling operation on south side
Republic Services called the development the “nation’s first integrated plastics recycling facility,” designed to address increasing demand from consumers and packaging manufacturers for recycled plastic.
Lilly bracing for demand crush for newly approved obesity drug
The Indianapolis-based drug company is ramping up manufacturing capacity to avoid possible shortages and to meet potentially huge demand in a nation where more than 40% of adults are classified as obese.
FDA approves Lilly’s diabetes drug for weight management
Eli Lilly and Co.’s hot-selling diabetes drug, Mounjaro, will now be sold for a second use, chronic weight management, using a separate brand name, Zepbound.
Community Health sets aside $75M in ‘potential settlement agreement’ with feds, whistleblower
If a settlement is reached, it could end a legal saga that has stretched out for more than nine years, involving nearly 700 filings in the federal court docket.
Lilly posts 3Q loss of $57M, cuts full-year profit guidance
Excluding nonrecurring items, the Indianapolis-based drugmaker posted adjusted earnings of 10 cents a share, beating Zacks consensus estimate of a loss of 11 cents a share.
Syra Health rings Nasdaq opening bell; shares slide to new low
The company was formed only three years ago and went public on Sept. 29 in an initial public offering that raised $5.3 million after expenses.
IU to spend $250M on new life-science institutes in Indy, faculty, labs, research
IU’s newest plans are intended to bolster enrollment and establish Indiana University Indianapolis as one of the country’s premier urban research universities.
Eskenazi Hospital to expand therapy dog program with $1M gift
At Eskenazi and other hospitals around central Indiana, therapy dogs are seen as part of the health care team—furry healing agents who bring smiles to patients, and perhaps even more.